Notice: This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OVAS vs. RENB, SKYE, IMUX, CNTX, DERM, PYXS, TELO, MNPR, ANRO, and MNOVShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Renovaro (RENB), Skye Bioscience (SKYE), Immunic (IMUX), Context Therapeutics (CNTX), Journey Medical (DERM), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), Monopar Therapeutics (MNPR), Alto Neuroscience (ANRO), and MediciNova (MNOV). These companies are all part of the "medical" sector. OvaScience vs. Renovaro Skye Bioscience Immunic Context Therapeutics Journey Medical Pyxis Oncology Telomir Pharmaceuticals Monopar Therapeutics Alto Neuroscience MediciNova OvaScience (NASDAQ:OVAS) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Does the media refer more to OVAS or RENB? In the previous week, Renovaro had 1 more articles in the media than OvaScience. MarketBeat recorded 1 mentions for Renovaro and 0 mentions for OvaScience. Renovaro's average media sentiment score of 0.94 beat OvaScience's score of 0.00 indicating that Renovaro is being referred to more favorably in the news media. Company Overall Sentiment OvaScience Neutral Renovaro Positive Do insiders and institutionals have more ownership in OVAS or RENB? 22.5% of OvaScience shares are owned by institutional investors. Comparatively, 71.4% of Renovaro shares are owned by institutional investors. 7.4% of OvaScience shares are owned by company insiders. Comparatively, 21.7% of Renovaro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, OVAS or RENB? OvaScience has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Does the MarketBeat Community favor OVAS or RENB? OvaScience received 274 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformOvaScienceOutperform Votes27463.87% Underperform Votes15536.13% RenovaroN/AN/A Is OVAS or RENB more profitable? Renovaro has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets OvaScience-10,128.37% -47.06% -42.39% Renovaro N/A -67.54%-52.89% Which has higher earnings and valuation, OVAS or RENB? OvaScience has higher revenue and earnings than Renovaro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvaScience$290K107.97-$50.97MN/AN/ARenovaroN/AN/A-$80.65M-$0.96-1.23 SummaryOvaScience beats Renovaro on 6 of the 11 factors compared between the two stocks. Ad True Gold RepublicFed Declares War on AmericansFed Declares War on Americans Protect your wealth in the coming months… [RUSH MY FREE GUIDE NOW] Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.31M$6.67B$5.18B$9.10BDividend YieldN/A7.94%5.36%4.00%P/E RatioN/A9.85129.5317.42Price / Sales107.97329.221,292.6481.45Price / CashN/A59.1741.9238.55Price / Book0.495.514.874.94Net Income-$50.97M$151.81M$118.66M$224.12M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$0.87-8.4%N/A-72.3%$31.31M$290,000.000.00N/AGap UpHigh Trading VolumeRENBRenovaro0.5827 of 5 stars$0.84+11.7%N/A-68.6%$134.10MN/A-0.7912News CoverageGap DownSKYESkye Bioscience1.8836 of 5 stars$4.39-2.2%$18.67+325.2%+154.9%$133.18MN/A0.0011Positive NewsGap DownIMUXImmunic3.4538 of 5 stars$1.36+9.3%$11.80+770.8%+5.8%$122.06MN/A0.0070CNTXContext Therapeutics3.1455 of 5 stars$1.61+5.9%$6.80+322.4%+60.1%$120.75MN/A-1.677Short Interest ↓Positive NewsDERMJourney Medical2.3042 of 5 stars$5.78flat$9.38+62.2%N/A$120.74M$79.18M-6.1590Short Interest ↑PYXSPyxis Oncology2.5011 of 5 stars$2.03+1.0%$10.00+392.6%+15.3%$120.72M$16.15M-1.9360TELOTelomir PharmaceuticalsN/A$4.00+0.5%N/AN/A$118.44MN/A0.001News CoveragePositive NewsHigh Trading VolumeMNPRMonopar Therapeutics1.9973 of 5 stars$22.15-1.7%$27.33+23.4%+1,304.2%$116.91MN/A-11.4410News CoverageANROAlto Neuroscience2.3787 of 5 stars$4.33-1.8%$20.00+361.9%N/A$116.78M$210,000.000.00N/AMNOVMediciNova1.8843 of 5 stars$2.38+15.0%$9.00+278.2%+29.2%$116.74M$1M-9.8610Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies RENB Competitors SKYE Competitors IMUX Competitors CNTX Competitors DERM Competitors PYXS Competitors TELO Competitors MNPR Competitors ANRO Competitors MNOV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OVAS) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A...Investors Alley | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredFed Declares War on AmericansFed Declares War on Americans Protect your wealth in the coming months… True Gold Republic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVAS Stock Alerts